1. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study

   • Yu Takahashi
   • Nobutake Yamamichi
   • Mitsuhiro Fujishiro

   Original Article 24 January 2022 Pages: 481 - 489

   

2. Gastric cancer exosomes contribute to the field cancerization of gastric epithelial cells surrounding gastric cancer

   • Jung Hwan Yoon
   • Byung Joon Choi
   • Won Sang Park

   Original Article 07 January 2022 Pages: 490 - 502

   

3. CAF promotes chemoresistance through NRP2 in gastric cancer

   • Yanpeng Yang
   • Yongchen Ma
   • Yucun Liu

   Original Article Open access 26 November 2021 Pages: 503 - 514

   

4. Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast

   • Yusuke Nakamura
   • Jun Kinoshita
   • Sachio Fushida

   Original Article Open access 07 January 2022 Pages: 515 - 526

   

5. LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway

   • Lingnan He
   • Anqi Feng
   • Ming Yang

   Original Article 30 January 2022 Pages: 527 - 541

   

6. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer

   • Lingfeng Fu
   • Atsuko Yonemura
   • Takatsugu Ishimoto

   Original Article 15 February 2022 Pages: 542 - 557

   

7. Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells

   • Shinichi Umeda
   • Mitsuro Kanda
   • Yasuhiro Kodera

   Original Article 28 February 2022 Pages: 558 - 572

   

8. rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori–infected individuals: a genome-wide association study in the Korean population

   • Cheol Min Shin
   • Kyungtaek Park
   • Dong Ho Lee

   Original Article 24 March 2022 Pages: 573 - 585

   

9. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

   • Kohei Shitara
   • Toshihiko Doi
   • David H. Ilson

   Original Article Open access 08 January 2022 Pages: 586 - 597

   

10. Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

    • Michael Jeffers
    • Christian Kappeler
    • Michael Teufel

    Original Article Open access 20 January 2022 Pages: 598 - 608

    

11. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

    • Bum Jun Kim
    • Hee-Jung Jee
    • Dae Young Zang

    Original Article 11 January 2022 Pages: 609 - 618

    

12. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

    • Hirotaka Hasegawa
    • Kohei Shitara
    • Yasuhiro Kodera

    Original Article Open access 07 March 2022 Pages: 619 - 628

    

13. Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer

    • Annamaria Agnes
    • Alberto Biondi
    • Domenico D’Ugo

    Original Article 22 November 2021 Pages: 629 - 639

    

14. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials

    • Hedde D. Biesma
    • Tanya T. D. Soeratram
    • Nicole C. T. van Grieken

    Original Article Open access 07 February 2022 Pages: 640 - 651

    

15. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma

    • Dag Holmberg
    • Joonas H. Kauppila
    • Jesper Lagergren

    Original Article Open access 15 February 2022 Pages: 652 - 658

    

16. A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy

    • Chunpeng Zhu
    • Hiroshi Kawachi
    • Xinliang Lu

    Case Report 18 February 2022 Pages: 659 - 664